{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-115800","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.798662+00:00","generated_at":"2026-05-30T12:21:00.493920+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Therapeutics completes enrollment in Phase 2a RIVER trial of Haduvio; topline data due Q1 2025","bullets":["Trevi Therapeutics (Nasdaq: TRVI) completed enrollment in its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER).","The trial is evaluating Haduvio for the treatment of refractory chronic cough.","Topline data from the RIVER trial is expected to be reported in the first quarter of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-115800","json":"https://secwatch.observer/filing/0000950170-24-115800.json","markdown":"https://secwatch.observer/filing/0000950170-24-115800.md","text":"https://secwatch.observer/filing/0000950170-24-115800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024115800/0000950170-24-115800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024115800/trvi-20241021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:21:00.493920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}